Nootropic guide
Bromantane (Ladasten): Dopamine, Fatigue and the Evidence
Bromantane is an adamantane-derived drug developed in Russia, sold there as Ladasten for asthenia (chronic fatigue and weakness). Unlike classic stimulants it does not block dopamine reuptake: in rat studies it switches on the genes for tyrosine hydroxylase and DOPA-decarboxylase, the enzymes that make dopamine. Human data is limited and mostly Russian-language.
Key takeaways
- Classified as an actoprotector: improves physical and mental work capacity without raising oxygen use or heat production.
- Mechanism (rats): more tyrosine hydroxylase and DOPA-decarboxylase gene expression, so the brain makes more dopamine.
- Also raises BDNF and NGF gene expression and affects serotonin in animal studies.
- Approved in Russia for asthenia. Not approved by the FDA or EMA, and prohibited by WADA.
In this guide
What is bromantane?
Bromantane (also spelled bromantan) is a synthetic adamantane derivative developed in the Soviet Union and later registered in Russia under the brand name Ladasten, for asthenia: persistent fatigue, low drive and weakness. Pharmacologists classify it as an actoprotector, a compound that improves the body's stability under physical load without increasing oxygen consumption or heat production [1]. In other words, a "synthetic adaptogen" rather than a classic stimulant.
How does bromantane work?
This is what makes bromantane interesting. Stimulants like amphetamine or methylphenidate push existing dopamine into the synapse or stop it from being cleared. Bromantane appears to raise the capacity to make dopamine:
- Dopamine synthesis genes. In rats, a single dose increased expression of the genes for tyrosine hydroxylase (TH) and DOPA-decarboxylase (DDC), the two enzymes that turn tyrosine into L-DOPA and L-DOPA into dopamine. L-DOPA and dopamine rose in the striatum and hypothalamus in step with that gene activity [2].
- Neurotrophins. It also increased gene expression for BDNF and NGF and activated the ERK1/2 signalling cascade in rat brain [3].
- Serotonin. Rat studies show increased serotonin and its metabolite in the frontal cortex [4].
The practical implication people care about: because it works upstream on synthesis rather than forcing release, it is described as producing less of a crash than classic stimulants. That idea is consistent with the mechanism, but it has not been tested head-to-head in proper trials.
What the research shows
| Area | Model | Finding | Source |
|---|---|---|---|
| Dopamine synthesis | Rats | Higher TH and DDC gene expression, more L-DOPA and dopamine | [2] |
| Neurotrophins | Rats | More BDNF and NGF gene expression, ERK1/2 activation | [3] |
| Serotonin and dopamine systems | Rats | Raised frontal-cortex serotonin, dopamine changes | [4] |
| Neurasthenia | Humans, vs placebo | Effect varied with patients' EEG alpha-rhythm profile | [5] |
| Fatigue in palliative care | Humans | Ladasten 100 mg in a combination protocol beat standard therapy for fatigue | [6] |
Is there human evidence?
Some, but it is thin by Western standards. Clinical work on Ladasten was published mainly in Russian journals, often in small samples, and much of it is not available in full in English. A placebo-controlled study in neurasthenia found that how well patients responded depended on their EEG alpha-rhythm pattern and personality profile [5]. A palliative-care study used 100 mg of Ladasten as part of a combination that outperformed standard fatigue treatment [6]. These are signals, not proof.
Is bromantane safe? Legal status
- Approval: registered in Russia (Ladasten). Not approved by the FDA or the EMA.
- Sport: bromantane is on the World Anti-Doping Agency (WADA) prohibited list. Tested athletes should not use it.
- Toxicology: Russian acute-toxicity work in animals mapped separate therapeutic, toxic and lethal dose ranges: therapeutic effects are catecholaminergic, while toxic doses act through cholinergic effects [7]. Long-term human safety data is limited.
- Because it acts on dopamine and serotonin, combining it with antidepressants, MAOIs or stimulants without medical supervision is a bad idea.
Frequently asked questions
What does bromantane do?
It is an actoprotector used in Russia (as Ladasten) for fatigue and low drive. In animal studies it increases the expression of the enzymes that make dopamine, rather than forcing dopamine release like classic stimulants.
Is bromantane a stimulant?
Not in the classic sense. It does not block dopamine reuptake. It is classified as an actoprotector, with mild stimulating effects reported alongside anti-fatigue effects.
Is bromantane legal in the US?
It is not FDA-approved. It is sold by some suppliers for research use only, and it is prohibited in sport by WADA.
What is the difference between bromantane and Ladasten?
Ladasten is the Russian pharmaceutical brand name for bromantane.
How long does bromantane take to work?
In rat studies dopamine effects began within hours, with gene-expression changes following. Human onset data in English is limited.
Keep reading
- Reset Your Brain's Reward System and Raise Your Dopamine Baseline.
- The Downfall of SSRI Drugs
- Fix your Gut to improve Mood and Cognitive Function.
More guides:
Sources
- Oliynyk S, Oh S The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul) 2012. PMID 24009833
- Vakhitova IuV, Iamidanov RS, Seredinin SB Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain. Eksp Klin Farmakol 2004. PMID 15500036
- Salimgareeva MKh, Yamidanov RS, Vakhitova YV et al. Mechanisms of action of ladasten: activation of gene expression for neurotrophins and mitogen-activated kinases. Bull Exp Biol Med 2012. PMID 22803074
- Kudrin VS, Sergeeva SA, Krasnykh LM et al. [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]. Eksp Klin Farmakol 1995. PMID 7580761
- Neznamov GG, Bochkarev VK, Reutova MA et al. Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types. Eksp Klin Farmakol 2012. PMID 22834121
- Ryazankina AA, Rozengard SA, Glushchenko VA et al. Optimization of pharmacological therapy for weakness syndrome in incurable patients. Vopr Onkol 2015. PMID 26087610
- Bugaeva LI, Verovskiĭ VE, Iezhitsa IN et al. [An acute toxicity study of bromantane]. Eksp Klin Farmakol 2000. PMID 10763112
This guide is educational and is not medical advice. Talk to a qualified clinician before starting any compound, especially if you take medication, are pregnant, or compete in tested sport.